Granulocyte Colony-Stimulating Factor Improves Endothelial Progenitor Cell-Mediated Neovascularization in Mice with

Shao-Yu Tang1, Yi-Chin Lee2, Chien-Wei Tseng3,4

  • 1Department of Medical Education, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.

Pharmaceutics
|October 28, 2023
PubMed

Insights

Granulocyte colony-stimulating factor (G-CSF) improves blood vessel growth in mice with chronic kidney disease and peripheral arterial disease. G-CSF enhances endothelial progenitor cell function, offering potential therapeutic benefits for patients.

Area of Science:

  • Cardiovascular Biology
  • Regenerative Medicine
  • Nephrology

Background:

  • Chronic kidney disease (CKD) is linked to increased peripheral arterial disease (PAD) risk.
  • Endothelial progenitor cells (EPCs) are crucial for repairing damaged blood vessels.
  • CKD impairs EPC function, contributing to PAD complications.

Purpose of the Study:

  • To investigate the effect of G-CSF on EPC function and angiogenesis in a mouse model of CKD with hindlimb ischemia.
  • To explore the underlying molecular mechanisms, including the role of IL-10 and hypoxia signaling.

Main Methods:

  • Subtotal nephrectomy (SNx) was performed on mice to induce CKD.
  • Hindlimb ischemia was surgically induced, followed by G-CSF or PBS treatment.
  • Limb reperfusion, EPC mobilization, angiogenesis, and protein expression were assessed.

Main Results:

  • SNx mice showed reduced limb reperfusion, impaired angiogenesis, and decreased EPC function compared to controls.
  • G-CSF treatment improved these parameters in SNx mice, associated with increased IL-10 levels.
  • G-CSF reversed the downregulation of key proteins (IL-10, phospho-STAT3, VEGF, phospho-eNOS) in ischemic tissues.

Conclusions:

  • G-CSF enhances EPC angiogenic function via a hypoxia/IL-10 signaling pathway in the context of CKD.
  • G-CSF can counteract the detrimental effects of CKD on neovascularization in ischemic limbs.
  • G-CSF holds promise for treating angiogenesis defects in CKD patients with PAD using EPC-based therapies.